Market Cap 20.92B
Revenue (ttm) 13.95B
Net Income (ttm) 876.50M
EPS (ttm) N/A
PE Ratio 15.08
Forward PE 14.13
Profit Margin 6.28%
Debt to Equity Ratio 0.67
Volume 475,761
Avg Vol 635,722
Day's Range N/A - N/A
Shares Out 82.00M
Stochastic %K 50%
Beta 0.91
Analysts Strong Sell
Price Target $311.47

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esote...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 336 229 1127
Address:
358 South Main Street, Burlington, United States
TalkMarkets
TalkMarkets Aug. 3 at 7:56 PM
#Replit’s Next Billion-Dollar Opportunity: From #AI Coding Platform To Entrepreneurship Development Platform Also: $LH $PYPL $TEAM $Z https://talkmarkets.com/article/replits-next-billion-dollar-opportunity-from-ai-coding-platform-to-entrepreneurship-development-platform-1785785420
0 · Reply
IN0V8
IN0V8 Aug. 3 at 4:22 PM
$LH Buy Opportunity JP Morgan raises target price to $360 from $330
0 · Reply
Estimize
Estimize Jul. 30 at 11:04 PM
$LH reported 4.99 EPS and 3,731 revenue for Q2. http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_content=LH&utm_medium
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 2:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-laboratory-co-of-america-holdings-stock/ $LH Labcorp Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 30 at 11:00 AM
$LH Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $3.66 up 28.42% YoY • Reported revenue of $3.73B up 5.78% YoY • Labcorp Holdings Inc. updated its full-year 2026 guidance, now projecting enterprise revenue growth of 5.4% to 6.3% and an adjusted EPS range of $18.10 to $18.55 at the midpoint.
0 · Reply
Small_time_trader
Small_time_trader Jul. 23 at 8:05 PM
$DGX $LH DGX >> LH
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jul. 21 at 3:03 PM
🚨 $INBS : Today's FDA Progress Update 🇺🇸 Today's news: Intelligent Bio Solutions announced it has successfully completed precision testing, another important step toward its FDA 510(k) submission and planned U.S. commercial launch. 🧪 Latest Update 🔹 Successfully completed precision testing, adding another key validation study to its FDA 510(k) submission. 🔹 The submission package now includes Precision, Method Comparison, Cut off, and Interference studies. 🔹 More than 1,600 tests were completed across 3 production runs and 3 independent testing sites, demonstrating consistent performance. 🔹 Targeting the U.S. drug screening market, estimated at over $5.8B today and projected to surpass $11.2B by 2034, with its fingerprint-based drug testing technology. 🔹 Results are available in under 10 minutes, with sample collection taking only seconds and no blood, urine, or saliva required. Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers:$CODX $FLGT $DGX $LH
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jul. 15 at 2:10 PM
🧬 $INBS : Could FDA Approval Unlock the Next Leg Higher? Intelligent Bio Solutions is developing a fingerprint based drug screening system that delivers fast, non invasive testing On June 16, the company kicked off another FDA clinical study, marking another step toward its planned 510(k) submission and potential entry into the U.S. drug testing market Recent Highlights: 🔹 FDA clinical program remains on track 🔹 135-patient U.S. multi site study underway 🔹 Operating in 35+ countries with 480+ active customer accounts 🔹 Q3 revenue increased 46% YoY to $1.06M 🔹 Nine-month revenue reached $3.07M, up 39% YoY 🔹 Gross margin climbed above 50% 🔹 Cash position increased to $6.86M 🔹 Secured its 8th European patent while expanding manufacturing capacity With several FDA milestones ahead, growing commercial traction, and improving financials, INBS looks like one to keep on the watchlist Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers : $OSUR $QDEL $DGX $LH
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 24 at 6:36 AM
$LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $18.59 – $22.96 Target Zone: $29.73 – $36.34 Potential Upside: 51% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 24 at 2:55 AM
$LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $17.25 – $21.32 Target Zone: $29.41 – $35.95 Potential Upside: 61% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on LH
Labcorp price target raised to $360 from $330 at JPMorgan

2026-08-03T11:37:12.000Z - 1 day ago

Labcorp price target raised to $360 from $330 at JPMorgan


Labcorp price target raised to $360 from $320 at BofA

2026-07-31T12:47:09.000Z - 4 days ago

Labcorp price target raised to $360 from $320 at BofA


Labcorp price target raised to $352 from $338 at Baird

2026-07-31T11:20:19.000Z - 4 days ago

Labcorp price target raised to $352 from $338 at Baird


Labcorp price target raised to $320 from $290 at Barclays

2026-07-30T18:56:13.000Z - 4 days ago

Labcorp price target raised to $320 from $290 at Barclays


Labcorp Holdings Earnings Call Transcript: Q2 2026

Jul 30, 2026, 9:00 AM EDT - 5 days ago

Labcorp Holdings Earnings Call Transcript: Q2 2026


Labcorp Holdings Earnings release: Q2 2026

Jul 30, 2026, 9:00 AM EDT - 5 days ago

Labcorp Holdings Earnings release: Q2 2026


Labcorp Holdings Slides: Q2 2026

Jul 30, 2026, 9:00 AM EDT - 5 days ago

Labcorp Holdings Slides: Q2 2026


Labcorp reports Q2 adjusted EPS $4.99, consensus $4.77

2026-07-30T11:01:41.000Z - 5 days ago

Labcorp reports Q2 adjusted EPS $4.99, consensus $4.77


Labcorp launches Marker by Labcorp Genetic Health Panel

2026-07-27T12:11:39.000Z - 8 days ago

Labcorp launches Marker by Labcorp Genetic Health Panel


Labcorp awarded $364.7M Defense Health Agency contract

2026-07-22T21:25:14.000Z - 12 days ago

Labcorp awarded $364.7M Defense Health Agency contract


Labcorp price target raised to $320 from $300 at BofA

2026-07-13T11:15:37.000Z - 22 days ago

Labcorp price target raised to $320 from $300 at BofA


Labcorp Declares Quarterly Dividend

Jul 9, 2026, 5:05 PM EDT - 25 days ago

Labcorp Declares Quarterly Dividend


Labcorp announces nationwide availability of ColoSense

2026-06-22T11:06:27.000Z - 6 weeks ago

Labcorp announces nationwide availability of ColoSense


Labcorp to Present at the Jefferies Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 2 months ago

Labcorp to Present at the Jefferies Global Healthcare Conference


Labcorp Holdings Transcript: AGM 2026

May 21, 2026, 9:00 AM EDT - 2 months ago

Labcorp Holdings Transcript: AGM 2026


Labcorp, Epic expand collaboration

2026-05-12T13:09:47.000Z - 3 months ago

Labcorp, Epic expand collaboration


Labcorp price target raised to $334 from $332 at Baird

2026-05-01T14:38:36.000Z - 3 months ago

Labcorp price target raised to $334 from $332 at Baird


Labcorp Holdings Earnings Call Transcript: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Labcorp Holdings Earnings Call Transcript: Q1 2026


Labcorp Holdings Earnings release: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Labcorp Holdings Earnings release: Q1 2026


Labcorp Holdings Slides: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Labcorp Holdings Slides: Q1 2026


Labcorp Holdings Quarterly report: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Labcorp Holdings Quarterly report: Q1 2026


Labcorp raises full-year forecasts on steady diagnostics demand

Apr 30, 2026, 8:04 AM EDT - 3 months ago

Labcorp raises full-year forecasts on steady diagnostics demand


Labcorp Holdings Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Labcorp Holdings Proxy statement: Proxy filing


Labcorp Holdings Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Labcorp Holdings Proxy statement: Proxy filing


Labcorp Holdings Earnings Call Transcript: Q4 2025

Feb 17, 2026, 9:00 AM EST - 6 months ago

Labcorp Holdings Earnings Call Transcript: Q4 2025


Labcorp Holdings Annual report: Q4 2025

Feb 17, 2026, 9:00 AM EST - 6 months ago

Labcorp Holdings Annual report: Q4 2025


Labcorp Holdings Earnings release: Q4 2025

Feb 17, 2026, 9:00 AM EST - 6 months ago

Labcorp Holdings Earnings release: Q4 2025


Labcorp Holdings Slides: Q4 2025

Feb 17, 2026, 9:00 AM EST - 6 months ago

Labcorp Holdings Slides: Q4 2025


Labcorp Announces 2025 Fourth Quarter and Full Year Results

Feb 17, 2026, 6:50 AM EST - 6 months ago

Labcorp Announces 2025 Fourth Quarter and Full Year Results


Labcorp Appoints John H. Sampson, M.D.

Feb 9, 2026, 8:30 AM EST - 6 months ago

Labcorp Appoints John H. Sampson, M.D.


Labcorp Appoints Victor Bulto to Board of Directors

Nov 24, 2025, 8:30 AM EST - 9 months ago

Labcorp Appoints Victor Bulto to Board of Directors


Labcorp Holdings Earnings Call Transcript: Q3 2025

Oct 28, 2025, 9:00 AM EDT - 10 months ago

Labcorp Holdings Earnings Call Transcript: Q3 2025


Labcorp Holdings Quarterly report: Q3 2025

Oct 28, 2025, 9:00 AM EDT - 10 months ago

Labcorp Holdings Quarterly report: Q3 2025


Labcorp Holdings Earnings release: Q3 2025

Oct 28, 2025, 9:00 AM EDT - 10 months ago

Labcorp Holdings Earnings release: Q3 2025


Labcorp Holdings Slides: Q3 2025

Oct 28, 2025, 9:00 AM EDT - 10 months ago

Labcorp Holdings Slides: Q3 2025


Labcorp Announces 2025 Third Quarter Results

Oct 28, 2025, 6:50 AM EDT - 10 months ago

Labcorp Announces 2025 Third Quarter Results


Labcorp Holdings Earnings Call Transcript: Q2 2025

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Labcorp Holdings Earnings Call Transcript: Q2 2025


Labcorp Holdings Quarterly report: Q2 2025

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Labcorp Holdings Quarterly report: Q2 2025


Labcorp Holdings Earnings release: Q2 2025

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Labcorp Holdings Earnings release: Q2 2025


Labcorp Holdings Slides: Q2 2025

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Labcorp Holdings Slides: Q2 2025


Labcorp Announces 2025 Second Quarter Results

Jul 24, 2025, 6:50 AM EDT - 1 year ago

Labcorp Announces 2025 Second Quarter Results


TalkMarkets
TalkMarkets Aug. 3 at 7:56 PM
#Replit’s Next Billion-Dollar Opportunity: From #AI Coding Platform To Entrepreneurship Development Platform Also: $LH $PYPL $TEAM $Z https://talkmarkets.com/article/replits-next-billion-dollar-opportunity-from-ai-coding-platform-to-entrepreneurship-development-platform-1785785420
0 · Reply
IN0V8
IN0V8 Aug. 3 at 4:22 PM
$LH Buy Opportunity JP Morgan raises target price to $360 from $330
0 · Reply
Estimize
Estimize Jul. 30 at 11:04 PM
$LH reported 4.99 EPS and 3,731 revenue for Q2. http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_content=LH&utm_medium
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 2:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-laboratory-co-of-america-holdings-stock/ $LH Labcorp Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 30 at 11:00 AM
$LH Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $3.66 up 28.42% YoY • Reported revenue of $3.73B up 5.78% YoY • Labcorp Holdings Inc. updated its full-year 2026 guidance, now projecting enterprise revenue growth of 5.4% to 6.3% and an adjusted EPS range of $18.10 to $18.55 at the midpoint.
0 · Reply
Small_time_trader
Small_time_trader Jul. 23 at 8:05 PM
$DGX $LH DGX >> LH
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jul. 21 at 3:03 PM
🚨 $INBS : Today's FDA Progress Update 🇺🇸 Today's news: Intelligent Bio Solutions announced it has successfully completed precision testing, another important step toward its FDA 510(k) submission and planned U.S. commercial launch. 🧪 Latest Update 🔹 Successfully completed precision testing, adding another key validation study to its FDA 510(k) submission. 🔹 The submission package now includes Precision, Method Comparison, Cut off, and Interference studies. 🔹 More than 1,600 tests were completed across 3 production runs and 3 independent testing sites, demonstrating consistent performance. 🔹 Targeting the U.S. drug screening market, estimated at over $5.8B today and projected to surpass $11.2B by 2034, with its fingerprint-based drug testing technology. 🔹 Results are available in under 10 minutes, with sample collection taking only seconds and no blood, urine, or saliva required. Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers:$CODX $FLGT $DGX $LH
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jul. 15 at 2:10 PM
🧬 $INBS : Could FDA Approval Unlock the Next Leg Higher? Intelligent Bio Solutions is developing a fingerprint based drug screening system that delivers fast, non invasive testing On June 16, the company kicked off another FDA clinical study, marking another step toward its planned 510(k) submission and potential entry into the U.S. drug testing market Recent Highlights: 🔹 FDA clinical program remains on track 🔹 135-patient U.S. multi site study underway 🔹 Operating in 35+ countries with 480+ active customer accounts 🔹 Q3 revenue increased 46% YoY to $1.06M 🔹 Nine-month revenue reached $3.07M, up 39% YoY 🔹 Gross margin climbed above 50% 🔹 Cash position increased to $6.86M 🔹 Secured its 8th European patent while expanding manufacturing capacity With several FDA milestones ahead, growing commercial traction, and improving financials, INBS looks like one to keep on the watchlist Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers : $OSUR $QDEL $DGX $LH
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 24 at 6:36 AM
$LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $18.59 – $22.96 Target Zone: $29.73 – $36.34 Potential Upside: 51% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 24 at 2:55 AM
$LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $17.25 – $21.32 Target Zone: $29.41 – $35.95 Potential Upside: 61% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AdamBrennan2
AdamBrennan2 Jun. 16 at 2:26 PM
$AMN came up on my Reversed DCF screener as pricing in most FCF decline.. potentially lots of value here.. $LH $GH $BTSG $DVA
0 · Reply
Nosh
Nosh Jun. 3 at 6:52 PM
$LH Added to starter.
0 · Reply
John_Wick1234
John_Wick1234 May. 29 at 11:37 AM
$LH Nice Double Bottom with good volume.
0 · Reply
BillionerOfKing
BillionerOfKing May. 8 at 5:19 AM
$LH Current Stock Price: $258.04 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.71 Exit: $4.20 ROI: 55% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 6 at 10:57 PM
$LH Current Stock Price: $256.92 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.65 Exit: $4.73 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 6:45 PM
$LH Price: $257.48 (+0.13%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.23% RSI: 37.3 | Momentum: Moderate Volume: -26.1% vs avg Volatility: 1.54% Support: $248.59 | Resistance: $279.71 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 5:33 PM
$LH Share Price: $252.43 Contract Selected: Nov 20, 2026 $250 Calls Buy Zone: $19.38 – $23.94 Target Zone: $31.22 – $38.15 Potential Upside: 52% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TheContessa
TheContessa May. 4 at 12:11 AM
$LH Based on 10 Wall Street analysts offering 12 month price targets for Labcorp Holdings in the last 3 months the average price target is $309.63 with a high forecast of $334.00 and a low forecast of $290.00. The average price target represents a nice gain. Tune out the FUD. ✅📶
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 30 at 11:03 AM
$LH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.37 up 32.68% YoY • Reported revenue of $3.54B up 5.75% YoY • Labcorp raised full-year 2026 enterprise revenue guidance to 5.0% to 6.1% and adjusted EPS guidance to a range of $17.70 to $18.35, reflecting an increase of 13 cents at the midpoint.
2 · Reply
prismmarketview
prismmarketview Apr. 15 at 5:28 PM
$LH announced the launch of its FDA‑cleared Fentanyl Urine Visual Test, the first rapid fentanyl test of its kind manufactured in the U.S. It delivers results in ~10 minutes for use in ERs, hospitals and clinics—critical when you’re triaging suspected exposure/overdose. https://prismmarketview.com/labcorp-unveils-10-minute-fda-cleared-fentanyl-test-for-emergency-settings/
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 1:35 PM
$LH up 10.2% in the past year, but are macro headwinds a threat? ⚠️ 🔍 Strategic test expansion in neurology, oncology, & autoimmune disease 🚀 🌍 Currency fluctuations & geopolitical tensions could dent overseas revenues Discover the full growth vs. risk analysis here 👉 https://www.zacks.com/stock/news/2878452/is-this-the-right-time-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2878452-body-35856&ADID=SYND_STOCKTWITS_TWEET_2_2878452_BODY_35856
0 · Reply